Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaniprevir with peg-IFN and RBV in Japanese patients with chronic hepatitis C
NCT01405560Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vaniprevir in hepatitis C (HCV), sponsored by Merck & Co.. Started Sep 2011; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01405560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01405560.